-
公开(公告)号：KR1020170141993A
公开(公告)日：2017-12-27
申请号：KR1020160075146
申请日：2016-06-16
Applicant: 충남대학교산학협력단
Abstract: 본발명은동맥경화증진단용바이오마커조성물, 동맥경화증진단용조성물, 상기조성물을포함하는동맥경화증진단용키트및 동맥경화증의진단에대한정보를제공하는방법에관한것이다. 본발명의동맥경화증진단용바이오마커조성물은환자의혈액을이용하여손쉽게동맥경화증발생위험을예측하거나, 동맥경화증을신속하고정확하게진단할수 있어, 동맥경화증과관련된의학및 진단산업에유용하게이용될수 있다.
Abstract translation: 本发明涉及一种用于动脉粥样硬化和动脉硬化的诊断试剂盒，包括一个诊断性生物标记，动脉硬化的组合物，动脉硬化诊断组合物，该组合物的诊断提供信息的方法。 本发明可用于的动脉硬化的诊断生物标记物的组合物预测动脉粥样硬化风险容易使用患者的血液，或者它可以快速，准确地诊断动脉粥样硬化，它是在动脉粥样硬化相关的医疗和诊断工业。
-
公开(公告)号：KR1020110078671A
公开(公告)日：2011-07-07
申请号：KR1020090135536
申请日：2009-12-31
Applicant: 충남대학교산학협력단
CPC classification number: C12Q1/6844 , C12Q1/6851 , C12Q1/6876 , C12Q2561/113 , C12Q2600/118 , C12Q2600/154 , G01N33/15
Abstract: PURPOSE: A method for predicting therapeutic response of VEGF-specific tyrosine kinase inhibitor(VEGF-specific TKI) is provided. CONSTITUTION: A method for predicting therapeutic response of VEGF-specific tyrosine kinase inhibitor(VEGF-specific TKI) comprises: a step of detecting methylation of VEFG receptor promoter in a biological sample; and a step of evaluating the result and predicting therapeutic response. A kit for predicting therapeutic response contains a device for checking methylation of VEGF gene promoter. The VEGF gene promoter is a FLT-1 or KDR gene promoter.
Abstract translation: 目的：提供一种预测VEGF特异性酪氨酸激酶抑制剂（VEGF特异性TKI）治疗反应的方法。 构成：预测VEGF特异性酪氨酸激酶抑制剂（VEGF特异性TKI）的治疗反应的方法包括：检测生物样品中VEFG受体启动子甲基化的步骤; 以及评估结果和预测治疗反应的步骤。 用于预测治疗反应的试剂盒含有检测VEGF基因启动子甲基化的装置。 VEGF基因启动子是FLT-1或KDR基因启动子。
-
公开(公告)号：KR101895767B1
公开(公告)日：2018-09-07
申请号：KR1020160075146
申请日：2016-06-16
Applicant: 충남대학교산학협력단
Abstract: 본발명은동맥경화증진단용바이오마커조성물, 동맥경화증진단용조성물, 상기조성물을포함하는동맥경화증진단용키트및 동맥경화증의진단에대한정보를제공하는방법에관한것이다. 본발명의동맥경화증진단용바이오마커조성물은환자의혈액을이용하여손쉽게동맥경화증발생위험을예측하거나, 동맥경화증을신속하고정확하게진단할수 있어, 동맥경화증과관련된의학및 진단산업에유용하게이용될수 있다.
-
4.发明公开Ｌ형 폴리감마글루탐산을 생산하는 신규 미생물 바실러스 메가테리움 토하 및 이로부터 생산된 Ｌ형 폴리감마글루탐산 有权新型微生物生产L型聚氨基葡糖酸和L型聚氨基葡萄糖酸的新型微生物MOHATERIUM TOHA
公开(公告)号：KR1020120063025A
公开(公告)日：2012-06-15
申请号：KR1020100124020
申请日：2010-12-07
Applicant: 주식회사 바이오리더스 , 국민대학교산학협력단 , 한국생명공학연구원 , 충남대학교산학협력단
CPC classification number: C12R1/11 , A23L33/135 , A23L33/175 , A61K8/88 , A61K38/02 , A61K2800/10 , A61Q19/00 , C12N1/20 , C12P21/02
Abstract: PURPOSE: A novel microorganism which produces L-type poly gamma glutamic acid is provided to obtain the poly gamma glutamic acid used as a thickening agent, and biodegradable plastic solvent. CONSTITUTION: A novel microorganism, Bacillus megaterium Toha(KCTC 11752BP), produces L-type poly gamma glutamic acid. The strain is derived from a fermented food. The strain has 16S rDNA sequence of sequence number 1 and produces the poly gamma glutamic acid at low salinity. A probiotic composition contains Bacillus megaterium Toha (KCTC 11752BP) and the poly gamma glutamic acid.
Abstract translation: 目的：提供一种产生L-型polyγ谷氨酸的新型微生物，以获得用作增稠剂的聚γ谷氨酸和可生物降解的塑料溶剂。 构成：一种新型微生物，巨大芽孢杆菌Toha（KCTC 11752BP）产生L-型polyγ谷氨酸。 该菌株来自发酵食物。 该菌株具有序列号1的16S rDNA序列，并产生低盐度的多聚谷氨酸。 益生菌组合物含有巨大芽孢杆菌Toha（KCTC 11752BP）和聚γ谷氨酸。
-
5.发明授权
公开(公告)号：KR100857861B1
公开(公告)日：2008-09-11
申请号：KR1020070103512
申请日：2007-10-15
Applicant: 주식회사 바이오리더스 , 한국생명공학연구원 , 충남대학교산학협력단
CPC classification number: C07K14/475
Abstract: A surface expression vector for fusion protein of Myo-2 peptide multimer and myostatin is provided to express the myostatin fusion protein on the surface of bacteria, and increase the blood antibody production, body weight and muscle amount of animals by orally administering the bacteria. A myostatin derived peptide Myo-2 has the amino acid sequence of SEQ ID NO:1. A Myo-2 peptide multimer is prepared by polymerizing 2-8 Myo-2 peptides. A fusion protein is prepared by fusing the Myo-2 peptide multimer with matured myostatin. A surface expression vector for fusion protein contains a gene encoding polygammaglutamic acid synthetase complex selected from pgsB(polygammaglutamic acid synthetase), pgsC and pgsA, the nucleotide sequence encoding the Myo-2 peptide multimer and a gene encoding the matured myostatin. A method for producing a fusion protein-surface expressed microorganism comprises the steps of: (a) expressing the fusion protein of myostatin derived peptide multimer and matured myostatin on the surface of microorganism by culturing a microorganism transformed with the surface expression vector; and (b) recovering the microorganism with surface expressed matured myostatin, wherein the microorganism is lactic acid bacterium. Further, the matured myostatin is be derived from mammal or birds.
Abstract translation: 提供Myo-2肽多聚体和肌生成抑制素融合蛋白的表达表达载体，以表达细菌表面的肌生成抑制素融合蛋白，并通过口服施用细菌增加动物的血液抗体产生，体重和肌肉量。 肌生长抑制素衍生肽Myo-2具有SEQ ID NO：1的氨基酸序列。 通过聚合2-8个Myo-2肽制备Myo-2肽多聚体。 通过将Myo-2肽多聚体与成熟的肌生成抑制素融合来制备融合蛋白。 用于融合蛋白的表面表达载体包含编码聚腺苷酸合成酶复合物的基因，其选自pgsB（polygammaglutamic acid synthetase），pgsC和pgsA，编码Myo-2肽多聚体的核苷酸序列和编码成熟肌肉生长抑制素的基因。 一种融合蛋白表面表达微生物的制备方法，包括以下步骤：（a）通过培养用表面表达载体转化的微生物，将肌生长抑制素衍生肽多聚体和成熟肌生成抑制素的融合蛋白表达在微生物表面上; 和（b）用表面表达成熟的肌生长抑制素回收微生物，其中微生物是乳酸菌。 此外，成熟的肌生成抑制素来源于哺乳动物或鸟类。
-
Patent Agency Ranking
公开(公告)号：KR101161063B1
公开(公告)日：2012-06-28
申请号：KR1020090135536
申请日：2009-12-31
Applicant: 충남대학교산학협력단
Abstract: 본 발명은 환자에 따라 선별적인 혈관내피세포성장인자 특이적 타이로신 카이네이즈 억제제(VEGF-Specific TKI) 치료요법을 적용할 수 있도록 혈관내피세포성장인자 특이적 타이로신 카이네이즈 억제제 치료 반응성 예측방법 및 키트를 제공하는 것에 대한 것이다. 본 발명에 따른 혈관내피세포성장인자수용체 유전자 프로모터(VEGFR promoter) 부분의 메틸화(Methylation) 여부 확인 및 평가에 의한 혈관내피세포성장인자 특이적 타이로신 카이네이즈 억제제 치료 반응성 예측방법 및 키트를 이용할 경우, 단기간에 효과적으로 혈관내피세포성장인자 특이적 타이로신 카이네이즈 억제제(VEGF-Specific TKI) 치료요법 적용대상 환자를 선별할 수 있어, 무분별한 치료요법 적용에 따른 환자의 경제적, 심리적 및 육체적 고통의 경감을 기대할 수 있다.
타이로신 카이네이즈 억제제, 메틸화, 치료반응성, 혈관내피세포성장인자수용체 유전자-
7.发明公开씀바귀뿌리 열수 추출물로부터 저분자량엔지오텐신전환효소 저해제를 제조하는 방법 및 상기 방법에 의해 제조된 저분자량엔지오텐신전환효소 저해제를 함유하는 식품 有权高分子量转氨酶抑制剂低分子量制备工艺从热水提取物
公开(公告)号：KR1020010068159A
公开(公告)日：2001-07-13
申请号：KR1020010023416
申请日：2001-04-30
Applicant: 충남대학교산학협력단
Abstract: PURPOSE: A manufacturing process for a low molecular weight of angiotensin converting enzyme(ACE) inhibitor from hot water extract of lettuce root is provided, which is an efficient and economical process. CONSTITUTION: The manufacturing process for a low molecular weight of ACE inhibitor from lettuce root comprises the steps of: removing an impurities by washing lettuce, separating its root, adding distilled water to the root, and extracting by making reflux for 2hrs at 100deg.C, 60deg.C; filtering, centrifuging for 30min. at 4deg.C, 8000rpm, and collecting the upper solution; ultra-filtering the upper solution using ultra-filter membrane(limit of M.W. is 1000) to prepare the extract; filtering through membrane filter paper, loading on high performance liquid chromatography, and separating a fraction, F4 with highest activity; and then gathering the F4, freeze-drying, and purifying using reversed phase HPLC.
Abstract translation: 目的：提供莴苣根热水提取物中低分子量血管紧张素转换酶（ACE）抑制剂的制备方法，这是一个有效和经济的过程。 构成：莴苣根的低分子量ACE抑制剂的制造过程包括以下步骤：通过洗莴苣，分离根，向根中加入蒸馏水，并在100℃回流2小时提取，除去杂质。 ，60deg.C 过滤，离心30min。 在4℃，8000rpm下收集上层溶液; 使用超滤膜（M.W.的限制为1000）对上部溶液进行超滤，以制备提取物; 通过膜滤纸过滤，装载高效液相色谱法，分离出一个具有最高活性的级分F4; 然后使用反相HPLC收集F4，冷冻干燥和纯化。
-
8.发明授权Ｌ형 폴리감마글루탐산을 생산하는 신규 미생물 바실러스 메가테리움 토하 및 이로부터 생산된 Ｌ형 폴리감마글루탐산 有权新型微生物巨大芽孢杆菌生产L型Poly Gamma谷氨酸和L型Poly Gamma谷氨酸由Therof生产
公开(公告)号：KR101269594B1
公开(公告)日：2013-06-05
申请号：KR1020100124020
申请日：2010-12-07
Applicant: 주식회사 바이오리더스 , 국민대학교산학협력단 , 한국생명공학연구원 , 충남대학교산학협력단
CPC classification number: C12R1/11 , A23L33/135 , A23L33/175 , A61K8/88 , A61K38/02 , A61K2800/10 , A61Q19/00 , C12N1/20 , C12P21/02
Abstract: 본 발명은 L형 폴리감마글루탐산을 생산하는 신규 미생물 및 그로부터 생산된 L형 폴리감마글루탐산에 관한 것으로, 더욱 자세하게는 한국의 전통 발효식품인 토하젓으로부터 분리된 바실러스 메가테리움 Toha (
Bacillus
megaterium Toha, KCTC11752BP) 및 상기 균주를 이용하여 생산된 폴리감마글루탐산에 관한 것이다.
본 발명에 따른 신규 미생물 바실러스 메가테리움 Toha (KCTC 11752BP)은 고부가가치의 미생물제제, 생균제제, 면역활성제, 동물용의약품 소재, 화장품 소재, 흡습제, 증점제 생분해성 플라스틱 용재로 사용될 수 있는 L형 폴리감마글루탐산을 생산하는 능력을 가진다.-
9.发明授权씀바귀뿌리 열수 추출물로부터 저분자량엔지오텐신전환효소 저해제를 제조하는 방법 및 상기 방법에 의해 제조된 저분자량엔지오텐신전환효소 저해제를 함유하는 식품 有权씀바귀뿌리열수추출물로부터저분자량엔지오텐신전환효소저해제를제조하는방법및상기방법에의해제조된저분자량엔지오텐신전환효소저해제를함유하는식품
公开(公告)号：KR100447534B1
公开(公告)日：2004-09-08
申请号：KR1020010023416
申请日：2001-04-30
Applicant: 충남대학교산학협력단
Abstract: PURPOSE: A manufacturing process for a low molecular weight of angiotensin converting enzyme(ACE) inhibitor from hot water extract of lettuce root is provided, which is an efficient and economical process. CONSTITUTION: The manufacturing process for a low molecular weight of ACE inhibitor from lettuce root comprises the steps of: removing an impurities by washing lettuce, separating its root, adding distilled water to the root, and extracting by making reflux for 2hrs at 100deg.C, 60deg.C; filtering, centrifuging for 30min. at 4deg.C, 8000rpm, and collecting the upper solution; ultra-filtering the upper solution using ultra-filter membrane(limit of M.W. is 1000) to prepare the extract; filtering through membrane filter paper, loading on high performance liquid chromatography, and separating a fraction, F4 with highest activity; and then gathering the F4, freeze-drying, and purifying using reversed phase HPLC.
Abstract translation: 目的：提供一种低分子量的生菜根热水提取物中的血管紧张素转化酶（ACE）抑制剂的制造工艺，这是一种高效且经济的工艺。 组成：低分子量生菜根ACE抑制剂的制造工艺包括以下步骤：通过洗涤生菜，分离其根，将蒸馏水加入根中，并通过在100℃回流2小时进行提取来除去杂质。 ，60deg.C; 过滤，离心30分钟。 在4℃，8000rpm下，收集上层溶液; 使用超滤膜（M.W.的极限为1000）超滤上层溶液以制备提取物; 通过膜滤纸过滤，上样于高效液相色谱仪，并分离出具有最高活性的馏分F4; 然后收集F4，冷冻干燥，并使用反相HPLC纯化。
-
公开(公告)号：KR1020020036981A
公开(公告)日：2002-05-17
申请号：KR1020020014640
申请日：2002-03-19
Applicant: 충남대학교산학협력단
Abstract: PURPOSE: A process for preparing low molecular weight angiotensin converting enzyme(ACE) inhibitor from the extract of wild chrysanthemum is provided, thereby effectively and cheaply preparing the ACE inhibitor. CONSTITUTION: The process for preparing low molecular weight angiotensin converting enzyme(ACE) inhibitor from the extract of wild chrysanthemum comprises the steps of: washing wild chrysanthemum with water and extracting it using a reflux condenser at 100 deg.C for 2 hours; filtering and centrifuging at 4 deg.C and 8000 rpm for 30 minutes to obtain the supernatant; ultrafiltering the supernatant with molecular weight cut off(MWCO) of 1000 dalton to obtain a crude extract of wild chrysanthemum; and sequentially subjecting the crude extract of wild chrysanthemum to gel filtration chromatography, HPLC, ion exchange chromatography and reverse HPLC to obtain the low molecular weight angiotensin converting enzyme(ACE) inhibitor.
Abstract translation: 目的：提供从野菊花提取物制备低分子量血管紧张素转换酶（ACE）抑制剂的方法，从而有效且廉价地制备ACE抑制剂。 构成：从野菊花提取物制备低分子量血管紧张素转换酶（ACE）抑制剂的方法包括以下步骤：用水洗涤野菊花，并在100℃下使用回流冷凝器提取2小时; 过滤并在4℃和8000rpm下离心30分钟，得到上清液; 超分子量截留（MWCO）为1000道尔顿的上清液，以获得野菊花的粗提物; 并依次对野菊花提取物进行凝胶过滤层析，HPLC，离子交换层析和反相HPLC，得到低分子量血管紧张素转换酶（ACE）抑制剂。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.021 seconds)
